• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

    3/6/25 1:36:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email

    PORTAGE, Mich., March 6, 2025 /PRNewswire/ -- Inari Medical, now part of Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its Artix Thrombectomy System. Purpose-built for the distinct needs of the peripheral arterial system, Artix is a combined aspiration plus mechanical thrombectomy solution that delivers procedural control and versatility, and is designed to set a new standard for arterial thrombectomy.

    Artix™ Thrombectomy System

    An arterial blood clot in the leg is a life- and limb-threatening emergency requiring immediate treatment. However, existing therapies for arterial thromboembolism can lead to:

    • Ineffective clot retrieval leading to additional procedures (open surgery or amputation1,2)
    • Significant blood loss1
    • Adverse events such as arterial embolization and vessel trauma2,3
    • High rates of lytic use, which may result in complications1,2

    The Artix System builds on the success of Inari's venous thrombectomy devices and is its inaugural entry into the arterial space. Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot.

    Jonathan Bowman, MD FACS, Chief of Vascular at Norwalk Hospital in Norwalk, CT, performed the first commercial case with Artix on October 19, 2024. "The Artix Thrombectomy System marks a significant advancement in peripheral arterial thromboembolism treatment," said Dr. Bowman. "With Artix, I finally have a solution that effectively addresses a wide range of clots while enabling me to maintain vessel access and retain control throughout the entire case. I expect Artix will take the place of open surgical repair in many of my arterial cases."

    Key distinctive features of the Artix system include:

    • Dual mechanical thrombectomy and aspiration toolkit designed to remove acute to chronic clots in a single session via a streamlined procedure4
    • Aspiration-capable, 8 Fr. low profile, trackable, kink-resistant sheath in both 65cm and 90cm lengths expands treatment options by enabling more complex and distal interventions
    • Innovative over-the-wire mechanical element designed to effectively collect and retrieve acute-to-chronic clot4
    • Covered nitinol mesh funnel provides temporary flow restriction during the procedure to minimize the risk of arterial clot migration5

    "There is a real clinical need to address chronic thrombi and decrease the risk of clot migration. Artix will raise the bar of effective arterial thrombectomy," said Tom Tu, MD, Chief Medical Officer of Inari Medical. "We are excited to bring Inari's core competency in thrombectomy to the arterial space with the goal of improving outcomes."

    For more information, visit https://www.inarimedical.com/artix-system

    About Stryker

    Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

    On February 19, 2025, Stryker acquired Inari Medical, a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases.

    Media contact:

    Sherri Oakson

    Senior Director, Communications 

    MedSurg and Neurotechnology

    [email protected] 

    1. De Donato et al. The INDIAN Trial. Eur J Vasc Endovasc Surg. 2021; 61: 820-828.
    2. Heller et al. Percutaneous Mechanical Thrombectomy Using Rotarex Device in Acute Limb Ischemia in Infrainguinal Occlusions. BioMed Research International. 2017.
    3. Olinic et al. Acute Limb Ischemia: An Update on Diagnosis and Management. J Clin Med. 2019.
    4. Designed to remove acute to chronic arterial clots. According to benchtop testing compared to control. Internal data on file. Narula et al. JACC 2018;72:2153-63
    5. According to benchtop testing compared to control. Internal data on file. NOTE: To attempt to minimize risk of arterial embolization of blood clots, use of a device that entraps clots may potentially be helpful, but this has not yet been demonstrated to be effective in the arterial system.

    Dr. Jonathan Bowman is a paid consultant of Inari Medical. All views and opinions expressed here by Dr. Jonathan Bowman are his own and do not represent those of Inari Medical.

    Indications for Use: The Artix thin-walled sheath is indicated for: (1) The non-surgical removal of emboli and thrombi from blood vessels. (2) Injection, infusion and/or aspiration of contrast media and other fluids into or from a blood vessel. (3) Use as a conduit for endovascular devices. (4) Use in facilitating the insertion and guidance of an intravascular catheter into a selected blood vessel. The funnel provides temporary vascular occlusion during these and other angiographic procedures. The Artix thin-walled sheath is intended for use in the peripheral vasculature. The Artix MT thrombectomy device is indicated for (1) the non-surgical removal of emboli and thrombi from a blood vessel; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix MT thrombectomy device is intended for use in the peripheral vasculature. The Artix AX aspiration catheter is indicated for (1) the non-surgical removal of emboli and thrombi from blood vessels; and (2) injection, infusion, and/or aspiration of contrast media and other fluids into or from a blood vessel. The Artix AX aspiration catheter is intended for use in the peripheral vasculature. The FlowSaver blood return system is used with Inari Medical catheters and sheaths for autologous blood transfusion.

    Review complete Instructions for Use, Indications for Use, Warnings, Precautions, Possible Adverse Effects and Contraindications prior to use of these products.

    Stryker Logo (PRNewsfoto/Stryker)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inari-medical-now-part-of-stryker-launches-artix-thrombectomy-system-designed-to-address-a-broad-spectrum-of-arterial-thrombus-cases-302394987.html

    SOURCE Stryker

    Get the next $SYK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    2/20/2026Outperform
    William Blair
    1/27/2026$387.00Hold
    TD Cowen
    1/6/2026$418.00Mkt Perform → Outperform
    Raymond James
    12/19/2025$440.00Mkt Perform → Mkt Outperform
    Citizens JMP
    9/18/2025$420.00Neutral
    Rothschild & Co Redburn
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    9/10/2024$405.00Outperform
    Wolfe Research
    More analyst ratings

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Stiles Spencer S

    4 - STRYKER CORP (0000310764) (Issuer)

    3/24/26 5:17:58 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Pierce James Andrew

    4 - STRYKER CORP (0000310764) (Issuer)

    3/24/26 5:14:47 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Menon Viju

    4 - STRYKER CORP (0000310764) (Issuer)

    3/24/26 5:11:39 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker to announce financial results for its first quarter of fiscal year 2026

    Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2026. Stryker will host a webcast at 4:30 p.m. ET on Thursday, April 30, 2026, to discuss its first quarter 2026 results.  The webcast can be accessed at Stryker - Events & Presentations.  An archive of the webcast will also be available on the company's website two hours afte

    4/1/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker names Nick Mead Vice President, Investor Relations

    Portage, Michigan, March 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Nick Mead has been appointed Vice President, Investor Relations, effective May 1, 2026. Mead has nearly 20 years of experience at Stryker, with leadership roles spanning multiple divisions and business units across the company. Most recently, he served as Vice President, Finance for Stryker's Medical division, where he partnered closely with senior leaders to support commercial strategy, capital allocation and operational execution. "Nick brings deep institutional knowledge, strong financial expertise and a proven ability to support strategic decision making

    3/31/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker announces Annual Meeting of Shareholders

    Portage, Michigan, March 23, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders is scheduled as follows: Wednesday, May 6, 2026 – 12:00 p.m. Eastern Time The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. A recording of the annual meeting will also be available from 10:30 a.m., Eastern Time, on Thursday, May 7, 2026 at www.virtualshareholdermeeting.com/SYK2026 until the definitive proxy statement for our 2027 Annual Meeting of Shareholders is

    3/23/26 3:00:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation

    SCHEDULE 13G/A - STRYKER CORP (0000310764) (Subject)

    3/27/26 1:20:03 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Stryker Corporation

    DEFA14A - STRYKER CORP (0000310764) (Filer)

    3/23/26 1:15:04 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Stryker Corporation

    DEF 14A - STRYKER CORP (0000310764) (Filer)

    3/23/26 1:05:14 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Stryker

    William Blair initiated coverage of Stryker with a rating of Outperform

    2/20/26 8:25:36 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    TD Cowen resumed coverage on Stryker with a new price target

    TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00

    1/27/26 8:50:06 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker upgraded by Raymond James with a new price target

    Raymond James upgraded Stryker from Mkt Perform to Outperform and set a new price target of $418.00

    1/6/26 8:28:26 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Financials

    Live finance-specific insights

    View All

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 15

    2/4/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports 2025 operating results and 2026 outlook

    Portage, Michigan, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2025: Fourth Quarter Results Reported net sales increased 11.4% to $7.2 billionOrganic net sales increased 11.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 100 bps to 30.2%Reported EPS increased 56.0% to $2.20Adjusted EPS(1) increased 11.5% to $4.47  Fourth Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        17.5        %         0.9        %         16.6        %         4.0        %         12.6        %

    1/29/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VB Spine Completes Acquisition of Cestas Manufacturing Facility from Stryker

    Deal expands global manufacturing footprint and positions VB Spine for future growth in spine care VB Spine LLC ("VB Spine") today completed the acquisition of Stryker's spine implant manufacturing facility in Cestas, France. Known for its state-of-the-art operations and technical capabilities, the Cestas facility will play a central role in VB Spine's global manufacturing strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106463289/en/VB Spine's manufacturing facility in Cestas, France This milestone expands on the April 1, 2025 formation of VB Spine, established through the acquisition of Stryker's U.S. spine implan

    1/6/26 8:57:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/12/24 10:18:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/14/23 12:37:55 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/10/23 9:18:16 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual Meeting

    Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy

    3/3/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care